First Time Loading...

Biomarin Pharmaceutical Inc
NASDAQ:BMRN

Watchlist Manager
Biomarin Pharmaceutical Inc Logo
Biomarin Pharmaceutical Inc
NASDAQ:BMRN
Watchlist
Price: 80.91 USD -1.56% Market Closed
Updated: Apr 28, 2024
Section:
 

Wall Street
Price Targets

BMRN Price Targets Summary
Biomarin Pharmaceutical Inc

Wall Street analysts forecast BMRN stock price to rise over the next 12 months.

According to Wall Street analysts, the average 1-year price target for BMRN is 111.89 USD with a low forecast of 80.8 USD and a high forecast of 147 USD.

BMRN Lowest Forecast
Wall Street Target
80.8 USD
0% Downside
BMRN Average Forecast
Wall Street Target
111.89 USD
38% Upside
BMRN Highest Forecast
Wall Street Target
147 USD
82% Upside
Lowest
Price Target
80.8 USD
0% Downside
Average
Price Target
111.89 USD
38% Upside
Highest
Price Target
147 USD
82% Upside

BMRN Last Price Targets
Biomarin Pharmaceutical Inc

The latest public price target was made on Apr 25, 2024 by George Farmer from Scotiabank , who expects BMRN stock to rise by 5% over the next 12 months. You can read more about this price target by viewing the article on StreetInsider.

Analyst Price Target Date Article
George Farmer
Scotiabank
85 USD
Upside 5%
3 days ago
Apr 25, 2024
BioMarin Pharmaceutical Inc. (BMRN) PT Raised to $85 at Scotiabank
StreetInsider
Eliana Merle
UBS
119 USD
Upside 47%
6 days ago
Apr 22, 2024
UBS Reiterates Buy Rating on BioMarin Pharmaceutical Inc. (BMRN)
StreetInsider
Kostas Biliouris
BMO Capital
102 USD
Upside 26%
9 months ago
Jul 5, 2023
BMO Capital Upgrades BioMarin Pharmaceutical Inc. (BMRN) to Outperform
StreetInsider
George Farmer
Scotiabank
Price Target 85 USD
Upside/Downside 5%
View Source
Eliana Merle
UBS
Price Target 119 USD
Upside/Downside 47%
View Source
Kostas Biliouris
BMO Capital
Price Target 102 USD
Upside/Downside 26%
View Source
Biomarin Pharmaceutical Inc Competitors:
Price Targets
300685
Amoy Diagnostics Co Ltd
41% Upside
KRYS
Krystal Biotech Inc
23% Upside
PANACEABIO
Panacea Biotec Ltd
52% Downside
KNSA
Kiniksa Pharmaceuticals Ltd
64% Upside
300685
Amoy Diagnostics Co Ltd
41% Upside
KRYS
Krystal Biotech Inc
23% Upside
PANACEABIO
Panacea Biotec Ltd
52% Downside
KNSA
Kiniksa Pharmaceuticals Ltd
64% Upside
ZYME
Zymeworks Inc
81% Upside
ABBV
Abbvie Inc
18% Upside
ORGO
Organogenesis Holdings Inc
110% Upside
4974
Takara Bio Inc
101% Upside

Revenue
Forecast

Revenue Estimate
Biomarin Pharmaceutical Inc

For the last 8 years the compound annual growth rate for Biomarin Pharmaceutical Inc's revenue is 13%. The projected CAGR for the next 3 years is 15%.

13%
Past Growth
15%
Estimated Growth
Estimates Accuracy
-2%
Average Miss
What are analyst estimates?

Operating Income
Forecast

Operating Income Estimate
Biomarin Pharmaceutical Inc

The compound annual growth rate of Biomarin Pharmaceutical Inc's operating income for the next 3 years is 86%.

N/A
Past Growth
86%
Estimated Growth
Estimates Accuracy
13%
Average Beat
What are analyst estimates?

Net Income
Forecast

Net Income Estimate
Biomarin Pharmaceutical Inc

The compound annual growth rate of Biomarin Pharmaceutical Inc's net income for the next 3 years is 66%.

N/A
Past Growth
66%
Estimated Growth
Estimates Accuracy
5%
Average Beat
What are analyst estimates?

See Also

Summary
BMRN intrinsic value, competitors valuation, and company profile.
DCF Valuation
BMRN stock valuation using Discount Cash Flow valuation method.
Relative Valuation
BMRN stock valuation using valuation multiples.
Wall Street Estimates
BMRN price targets and financial estimates made by Wall st analysts.
Profitability Analysis
Detailed analysis of the company's profitability.
Solvency Analysis
Analysis of the financial position and solvency of the company.
Financials
Income Statement, Balance Sheet, Cash Flow Statement.
Discount Rate
BMRN stock discount rate: cost of equity and WACC.
Summary
DCF Valuation
Relative Valuation
Wall Street Estimates
Profitability Analysis
Solvency Analysis
Financials
Discount Rate
Discover More
Why do you have more estimates than other sites?

Our estimates are sourced from the pool of sell-side and buy-side analysts that we have access to. What is available on other sites you are seeing are mostly from the sell-side analysts.

What is BMRN's stock price target?
Price Target
111.89 USD

According to Wall Street analysts, the average 1-year price target for BMRN is 111.89 USD with a low forecast of 80.8 USD and a high forecast of 147 USD.

What is Biomarin Pharmaceutical Inc's Revenue forecast?
Projected CAGR
15%

For the last 8 years the compound annual growth rate for Biomarin Pharmaceutical Inc's revenue is 13%. The projected CAGR for the next 3 years is 15%.

What is Biomarin Pharmaceutical Inc's Operating Income forecast?
Projected CAGR
86%

The compound annual growth rate of Biomarin Pharmaceutical Inc's operating income for the next 3 years is 86%.

What is Biomarin Pharmaceutical Inc's Net Income forecast?
Projected CAGR
66%

The compound annual growth rate of Biomarin Pharmaceutical Inc's net income for the next 3 years is 66%.

ALPHA SPREAD
Join more than 132,000+ value investors using Alpha Spread
Create a free account
or see our plans & pricing

Company

About Us Careers Pricing Affiliate Program Terms of Service Privacy Policy

Help

What is Intrinsic Value? Help Center Contact Us

Tools

Stock Screener Intrinsic Value Calculator DCF Value Calculator Discount Rate Calculator

Stocks

Most Undervalued Stocks High Profitability Stocks High Solvency Stocks Most Popular Stocks

© 2024 Alpha Spread Limited. All Rights Reserved.

www.alphaspread.com is not operated by a broker, a dealer, or a registered investment adviser. Under no circumstances does any information posted on www.alphaspread.com represent a recommendation to buy or sell a security. The information on this site, and in its related newsletters, is not intended to be, nor does it constitute, investment advice or recommendations. The information on this site is in no way guaranteed for completeness, accuracy or in any other way. In no event shall Alpha Spread Limited be liable to any member, guest or third party for any damages of any kind arising out of the use of any content or other material published or available on www.alphaspread.com, or relating to the use of, or inability to use, www.alphaspread.com or any content, including, without limitation, any investment losses, lost profits, lost opportunity, special, incidental, indirect, consequential or punitive damages. Past performance is a poor indicator of future performance.